商品名：Digimerck (European)
Cardiac inotropic agent. Digitoxin increases cardiac contractility and decreases heart rate. The mechanism is via inactivation of cardiac muscle sodium–potassium ATPase and increased intracellular accumulation of calcium, triggering calcium release from the sarcoplasmic reticulum. In addition, neuroendocrine effects include sensitization of baroreceptors, which decreases heart rate. Beneficial effects for heart failure may be via these neuroendocrine effects.
Digitoxin is indicated in patients with myocardial failure and to control the rate of supraventricular tachycardias. Digitoxin formulation availability for treating patients is limited. Digitoxin is no longer be obtained in the US. Subsequently, most of the digitoxin use has been replaced by digoxin. Digoxin is an active metabolite of digitoxin and may be used instead of digitoxin. Digoxin 231 D Instructions for Use Use of digitoxin has diminished in recent years in favor of digoxin. If available, it may be used with other cardiac drugs. Patient Monitoring and Laboratory Tests Monitor serum digoxin concentrations in patients to determine optimum therapy. When monitoring, collect blood samples 2-6 hours after dosing. The therapeutic range is 10-30 ng/mL. Formulations Digitoxin was once avai
劑量數字暫停提供：VetPro 的劑量改依 DRUGAPI 藥物資料庫對外的內容，DRUGAPI 目前不提供可直接計算的劑量。下方列出 DRUGAPI 的審查結論與劑量審查引用的來源；計算機可手動輸入劑量換算。
沒有確認現行犬貓產品或現代驗證療程。核心犬用 5–10 mg/kg 比歷史單次犬用資料高約 150–300 倍，貓用文字則疑似混入 digoxin；歷史資料又受產品、年代、採血與檢驗方法限制。所有犬貓計算與飼主劑量均封鎖。
依出現頻率分組；嚴重副作用獨立列出，臨床上需立即辨識。